Design Therapeutics, Inc.(DSGN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
DSGN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Design Therapeutics, Inc. (DSGN), a Healthcare sector company. DSGN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Design Therapeutics, Inc. reports net income of $-17.6M, free cash flow of $-16.4M. Top institutional holders of DSGN by reported 13-F value include SR ONE CAPITAL MANAGEMENT,, RA CAPITAL MANAGEMENT, L.P., Point72 Asset Management, L.P., based on the most recent SEC filings. DSGN trades on the Nasdaq exchange and files with the SEC under CIK 1807120. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DSGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Design Therapeutics, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$0.00
Net Income
Q1 2026
$-17.6M
Free Cash Flow
Q1 2026
$-16.4M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
-40.7% YoYOperating Income
-27.4% YoYEPS (Diluted)
-38.6% YoYTotal Assets
-10.3% YoYOp. Cash Flow
-26.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — | — | $226.0K |
| Net Income | $-69.8M -40.7% | $-49.6M +25.8% | $-66.9M -5.6% | $-63.3M -78.2% | $-35.5M -329.1% | $-8.3M |
| Operating Income | $-79.5M -27.4% | $-62.4M +20.2% | $-78.2M -15.7% | $-67.6M -88.6% | $-35.8M -330.1% | $-8.3M |
| EPS (Diluted) | $-1.22 -38.6% | $-0.88 +26.1% | $-1.19 -4.4% | $-1.14 -48.1% | $-0.77 | — |
| Total Assets | $226.2M -10.3% | $252.1M -13.0% | $289.6M -15.1% | $341.1M -12.7% | $390.6M +969.6% | $36.5M |
| Operating Cash Flow | $-54.4M -26.1% | $-43.1M +26.4% | $-58.6M -14.1% | $-51.3M -74.7% | $-29.4M -238.9% | $-8.7M |
Get alerted when DSGN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Design Therapeutics, Inc. including:
Top Institutional Holders of DSGN
SR ONE CAPITAL MANAGEMENT, LP
$69.4M6,526,476 shRA CAPITAL MANAGEMENT, L.P.
$31.6M2,972,973 shPoint72 Asset Management, L.P.
$29.0M2,722,754 shBAKER BROS. ADVISORS LP
$27.5M2,585,978 shBlackRock, Inc.
$22.7M2,133,764 shLogos Global Management LP
$20.7M1,950,000 shDRIEHAUS CAPITAL MANAGEMENT LLC
$18.6M1,744,987 shVivo Capital, LLC
$17.2M1,612,903 shAlmitas Capital LLC
$16.3M1,530,335 shVANGUARD CAPITAL MANAGEMENT LLC
$14.4M1,349,850 sh
| Fund | Value | Shares |
|---|---|---|
| SR ONE CAPITAL MANAGEMENT, LP | $69.4M | 6,526,476 |
| RA CAPITAL MANAGEMENT, L.P. | $31.6M | 2,972,973 |
| Point72 Asset Management, L.P. | $29.0M | 2,722,754 |
| BAKER BROS. ADVISORS LP | $27.5M | 2,585,978 |
| BlackRock, Inc. | $22.7M | 2,133,764 |
| Logos Global Management LP | $20.7M | 1,950,000 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $18.6M | 1,744,987 |
| Vivo Capital, LLC | $17.2M | 1,612,903 |
| Almitas Capital LLC | $16.3M | 1,530,335 |
| VANGUARD CAPITAL MANAGEMENT LLC | $14.4M | 1,349,850 |
More Healthcare Companies
View all Healthcare →Put DSGN on your watchlist
Track score changes the day Design Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DSGN a good stock to buy?
13F Pro's AI-powered analysis of Design Therapeutics, Inc. (DSGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DSGN are available on the DSGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own DSGN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DSGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Design Therapeutics, Inc.'s investment landscape.